Event-Driven Stocks

ALLERGAN INC

Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕

Signs5 gooddetails ↓

Financials

SEC XBRL · annual
 FY14FY13FY12FY11FY10FY09
Revenue$7.24B$6.30B$5.65B$5.22B$4.92B$4.50B
Operating income$2.01B$1.81B$1.61B$1.37B$258.6M$928.0M
Net income$1.52B$985.1M$1.10B$934.5M$600,000$621.3M
Total assets$12.42B$10.57B$9.18B$8.51B$8.31B$7.54B
Total liabilities
Equity$7.75B$6.46B$5.84B$5.31B$4.76B$4.82B
EPS (diluted)$5.01$3.26$3.58$3.01$0.00$2.03
Shares out.307.6M307.5M307.5M307.5M307.5M305.8M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2014
Operating margin
27.8%
Net margin
21.1%
Return on equity
19.7%
Return on assets
12.3%
Return on capital (ROCE)
18.5%
Liabilities / assets
Debt / equity
Book value / share
$25.21
Revenue growth (YoY)
14.9%
Net income growth (YoY)
54.7%

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2014
Accruals / assets
3.3%clean
Piotroski F-Score
5/8mixed

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
87
/ 100
Profitability 100Growth 100Catalyst 33Earnings quality 100Financial strength 100

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →

Signs

5 good
  • Operating margin is positive
  • Strong return on equity (>15%)
  • Revenue is growing year-over-year
  • Positive operating cash flow
  • Clean earnings (low accruals)

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

FDA-approved drugs

openFDA · most recent
  • GELNIQUE 3%Dec 7, 2011
  • TRETINOINMar 22, 2010
  • TRIVARISJun 16, 2008
  • BYSTOLICDec 17, 2007
  • SANCTURA XRAug 3, 2007
  • NAMENDAApr 18, 2005
  • SANCTURAMay 28, 2004
  • ELESTATOct 16, 2003

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (4)

Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.